Skip to content

Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings

Randomized, Single-Blind, Monocentric, Non-Inferiority Trial of Gadopiclenol (Vueway®) Contrast Agent Performance vs. Gadobutrol (Gadovist®) in the Workup of Incidental Renal and Adrenal Findings

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07040865
Acronym
IRAF-WORKUP
Enrollment
104
Registered
2025-06-27
Start date
2025-08-18
Completion date
2027-07-31
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspect Renal and Adrenal Imaging Findings

Brief summary

The purpose of this study is to compare the effects of the contrast agent Gadopiclenol with those of the standard contrast agent Gadobutrol. The main question of this study is : Does gadopiclenol offer diagnostic properties that are equally effective as those of gadobutrol? Participants will be: * randomly assigned to one of two groups: the experimental group, which receives gadopiclenol, or the control group, which receives gadobutrol. Each participant is informed of their group allocation prior to the magnetic resonance imaging (MRI) scan. * invited for a single MRI appointment lasting approximately 60 minutes

Interventions

Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadobutrol contrast injection.

Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadopiclenol contrast injection.

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* signed informed consent * age ≥18 years * compatibility with magnetic resonance imaging * planned workup of kidney incidental finding or adrenal incidental findings (or both) * body mass index (BMI) \< 31 kg/m2

Exclusion criteria

* patients with implants that might affect imaging parameters in the region under investigation, as judged by the principal investigator * vulnerable individuals * claustrophobic individuals * individuals that are cognitively impaired or unable to understand the language * pregnant or breastfeeding patients

Design outcomes

Primary

MeasureTime frameDescription
Enhancement of the kidney and adrenal tissue60s and 15min after contrast injection during the one and only imaging sessionThe primary endpoint is the enhancement of the kidney and adrenal tissue (difference of T1, longitudinal relaxation time, of the organ signal before and after contrast agent application) in both contrast agent groups 60s and 15min after contrast injection.

Countries

Switzerland

Contacts

Primary ContactGrazia M. Cereghetti, PhD
graziamaria.cereghetti@insel.ch+41 31 632 65 80

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026